MJN110
Product Specifications
UNSPSC Description
MJN110 is an orally active and selective monoacylglycerol lipase (MAGL) inhibitor with IC50s of 9.1 nM and 2.1 nM for hMAGL and 2-arachidonoylglycerol (2-AG), respectively[1]. MJN110 produces opioid-sparing effects and displays strong antihyperalgesic activity[2].
Target Antigen
MAGL
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/mjn110.html
Purity
99.49
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(N1CCN(C(C2=CC=C(Cl)C=C2)C3=CC=C(Cl)C=C3)CC1)ON4C(CCC4=O)=O
Molecular Weight
462.33
References & Citations
[1]Wilkerson JL, et al. The Selective Monoacylglycerol Lipase Inhibitor MJN110 Produces Opioid-Sparing Effects in a Mouse Neuropathic Pain Model. J Pharmacol Exp Ther. 2016 Apr;357(1):145-56.|[2]Niphakis MJ, et al. Evaluation of NHS carbamates as a potent and selective class of endocannabinoid hydrolase inhibitors. ACS Chem Neurosci. 2013 Sep 18;4(9):1322-32.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-117474/MJN110-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-117474/MJN110-SDS-MedChemExpress.pdf
Clinical Information
No Development Reported
CAS Number
1438416-21-7
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
E6386 96 Tests
Leucine-rich repeat and Fibronectin Type III domain-containing protein 2 (LRFN2) Human ELISA Kit
Ask
View Details 
